

UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF NEW YORK

JEANINE A. SORTISIO and STEVEN R.
SORTISIO,

Plaintiffs,

v.

PETER ACCETTA, M.D., SUSAN M.
PETERSON, RPA-C, ASTELLAS PHARMA
US, INC., and NOVARTIS
PHARMACEUTICALS CORPORATION,

Defendants.

Civil Action No.: 1:09-CV-00176-RJA

Document electronically filed.

**RULE 7.1 DISCLOSURE
STATEMENT OF
ASTELLAS PHARMA US, INC.**

Defendant Astellas Pharma US, Inc. (“APUS”) by counsel and in compliance with Fed. R. Civ. P. 7.1, states as follows

1. APUS was formed following a merger involving Fujisawa Healthcare, Inc. (“FHI”) and is a successor of FHI. Fujisawa Pharmaceutical Co., Ltd. (“Fujisawa”) was a company organized and existing under the laws of Japan. Fujisawa, however, ceased to exist as a legal entity following the merger between Fujisawa and Yamanouchi Pharmaceutical Co., Ltd. (“Yamanouchi”) on April 1, 2005. Yamanouchi then changed its name to Astellas Pharma, Inc., (“API”), a Japanese company. Following the merger, FHI ceased to exist as a legal entity.

2. APUS is a subsidiary of Astellas US Holding, Inc., which is a subsidiary of API.

3. No publicly traded company owns 10% or more of the stock of APUS or API.

Respectfully submitted,

BY: /s/ Scott R. Jennette

Scott R. Jennette

Sharon M. Porcellio

WARD NORRIS HELLER & REIDY LLP

*Local Counsel for Defendant Astellas Pharma US,
Inc.*

300 State St.

Rochester, NY 14614

Harvey L. Kaplan

Mark C. Hegarty

SHOOK, HARDY & BACON L.L.P.

2555 Grand Boulevard

Kansas City, MO 64108

Counsel for Defendant Astellas Pharma US, Inc.

CERTIFICATE OF SERVICE

I hereby certify that on this 6th day of March, 2009, a true and correct copy of the foregoing document was served via the Court's electronic notification system upon:

David W. Olson
BROWN CHIARI
5775 Broadway
Lancaster, New York 14086-2360

Counsel for Plaintiffs

Peter J. Skalaban Jr.
SPRIGGS & HOLLINGSWORTH
1350 I Street NW
Washington, DC 20005

*Counsel for Defendant
Novartis Pharmaceuticals Corporation*

/s/ Scott R. Jennette
Counsel for Defendant Astellas Pharma US, Inc.